AU2018243836B9 - Gut-selective sequestering agents for the treatment and prevention of autism and related disorders - Google Patents

Gut-selective sequestering agents for the treatment and prevention of autism and related disorders Download PDF

Info

Publication number
AU2018243836B9
AU2018243836B9 AU2018243836A AU2018243836A AU2018243836B9 AU 2018243836 B9 AU2018243836 B9 AU 2018243836B9 AU 2018243836 A AU2018243836 A AU 2018243836A AU 2018243836 A AU2018243836 A AU 2018243836A AU 2018243836 B9 AU2018243836 B9 AU 2018243836B9
Authority
AU
Australia
Prior art keywords
sequestrant
subject
activated carbon
mice
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018243836A
Other languages
English (en)
Other versions
AU2018243836B2 (en
AU2018243836A1 (en
Inventor
Anthony Stewart Campbell
David H. Donabedian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axial Therapeutics Inc
Original Assignee
Axial Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axial Therapeutics Inc filed Critical Axial Therapeutics Inc
Publication of AU2018243836A1 publication Critical patent/AU2018243836A1/en
Assigned to AXIAL THERAPEUTICS, INC. reassignment AXIAL THERAPEUTICS, INC. Amend patent request/document other than specification (104) Assignors: AXIAL BIOTHERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2018243836B2 publication Critical patent/AU2018243836B2/en
Publication of AU2018243836B9 publication Critical patent/AU2018243836B9/en
Priority to AU2021206871A priority Critical patent/AU2021206871B2/en
Priority to AU2022200220A priority patent/AU2022200220A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018243836A 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders Ceased AU2018243836B9 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021206871A AU2021206871B2 (en) 2017-03-31 2021-07-22 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
AU2022200220A AU2022200220A1 (en) 2017-03-31 2022-01-14 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480039P 2017-03-31 2017-03-31
US62/480,039 2017-03-31
PCT/US2018/025607 WO2018183986A1 (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021206871A Division AU2021206871B2 (en) 2017-03-31 2021-07-22 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Publications (3)

Publication Number Publication Date
AU2018243836A1 AU2018243836A1 (en) 2019-11-21
AU2018243836B2 AU2018243836B2 (en) 2021-04-22
AU2018243836B9 true AU2018243836B9 (en) 2021-05-13

Family

ID=63677186

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018243836A Ceased AU2018243836B9 (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
AU2021206871A Ceased AU2021206871B2 (en) 2017-03-31 2021-07-22 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
AU2022200220A Abandoned AU2022200220A1 (en) 2017-03-31 2022-01-14 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021206871A Ceased AU2021206871B2 (en) 2017-03-31 2021-07-22 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
AU2022200220A Abandoned AU2022200220A1 (en) 2017-03-31 2022-01-14 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Country Status (9)

Country Link
US (4) US10617718B2 (https=)
EP (1) EP3600349A4 (https=)
JP (1) JP6978122B2 (https=)
KR (1) KR102328323B1 (https=)
CN (2) CN110944650B (https=)
AU (3) AU2018243836B9 (https=)
BR (1) BR112019020289A2 (https=)
CA (2) CA3191747A1 (https=)
WO (1) WO2018183986A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019020289A2 (pt) 2017-03-31 2020-09-01 Axial Biotherapeutics, Inc. agentes sequestrantes seletivos do intestino para o tratamento ou prevenção de autismo e distúrbios relacionados
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2021011481A1 (en) * 2019-07-12 2021-01-21 The General Hospital Corporation Anti-inflammatory factors
CA3164484A1 (en) * 2019-12-19 2021-06-24 Hill's Pet Nutrition, Inc. Compositions and methods of treating and reducing risk of conditions associated with elevated 4-ethylphenyl sulfate in canines using tomato pomace and methods of identifying canines at risk of such conditions
US20240197795A1 (en) * 2020-07-27 2024-06-20 Boadie DUNLOP Assessment and treatment of depression, anxiety, or related disorders
CN113440522B (zh) * 2021-07-29 2022-12-13 中山大学附属第七医院(深圳) 一种吲哚丙酸在制备用于治疗自闭症药物中的应用
CN115825314A (zh) * 2021-09-17 2023-03-21 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物s-甲基-5′-硫代腺苷及其应用
WO2023154547A1 (en) 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Colon targeted drug delivery
WO2023154966A1 (en) * 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Compositions and methods for sequestering metabolites in the gastrointestinal tract
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140065132A1 (en) * 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761284A (en) 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS5673542A (en) * 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP2008523100A (ja) * 2004-12-13 2008-07-03 アリーナ ファーマシューティカルズ， インコーポレイテッド ５ｈｔ２ｃ受容体に関連した疾患の治療に有用な５ｈｔ２ｃ受容体のモジュレータとしてのｎ−ビアリール及びｎ−アリールヘテロアリール２−置換ピペラジン誘導体
CA2754203A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
KR101593287B1 (ko) * 2011-03-04 2016-02-11 가부시끼가이샤 구레하 정제형의 경구 투여용 조성물 및 그의 제조 방법
US20140213534A1 (en) * 2011-05-23 2014-07-31 Thomas Jefferson University Intestinal hyperpermeability and prevention of systemic disease
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
TWI520751B (zh) 2013-02-22 2016-02-11 吳羽股份有限公司 經口投予用吸附劑及腎疾病治療劑及肝疾病治療劑
MX2016000293A (es) 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
US10071089B2 (en) * 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9763903B2 (en) * 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
WO2015150590A1 (en) * 2014-04-04 2015-10-08 Biotechnobel Sa Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract
BR112019020289A2 (pt) 2017-03-31 2020-09-01 Axial Biotherapeutics, Inc. agentes sequestrantes seletivos do intestino para o tratamento ou prevenção de autismo e distúrbios relacionados

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140065132A1 (en) * 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder

Also Published As

Publication number Publication date
CA3095724A1 (en) 2018-10-04
NZ758692A (en) 2022-03-25
WO2018183986A1 (en) 2018-10-04
CN114569633A (zh) 2022-06-03
BR112019020289A2 (pt) 2020-09-01
CN114569633B (zh) 2023-11-17
KR102328323B1 (ko) 2021-11-19
AU2022200220A1 (en) 2022-02-10
CN110944650B (zh) 2022-03-04
US20180303876A1 (en) 2018-10-25
JP2020513032A (ja) 2020-04-30
US10617718B2 (en) 2020-04-14
AU2018243836B2 (en) 2021-04-22
AU2021206871A1 (en) 2021-08-12
AU2018243836A1 (en) 2019-11-21
US20230364135A1 (en) 2023-11-16
CN110944650A (zh) 2020-03-31
AU2021206871B2 (en) 2021-10-14
EP3600349A1 (en) 2020-02-05
US11007219B2 (en) 2021-05-18
JP6978122B2 (ja) 2021-12-08
US20200368276A1 (en) 2020-11-26
CA3191747A1 (en) 2018-10-04
US20200390809A1 (en) 2020-12-17
KR20200024133A (ko) 2020-03-06
CA3095724C (en) 2023-04-18
EP3600349A4 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
AU2021206871B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
JP2022088641A (ja) 細菌株を含む組成物
Zhai et al. Probiotics bring new hope for atherosclerosis prevention and treatment
Zhang et al. Research progress of microbiota-gut-brain axis in Parkinson's disease
JP6884889B2 (ja) 細菌株を含む組成物
JP2022517754A (ja) 菌株、組成物および使用方法
KR20220094211A (ko) 세로토닌 생산 박테리아
Nápoles-Medina et al. Oral administration of Lactobacillus inhibits the permeability of blood‐brain and gut barriers in a parkinsonism model
KR20220034816A (ko) 박테리아 균주를 포함하는 조성물
Shi et al. Production, Mechanisms, and Therapeutic Strategies of Tryptophan Metabolites in CNS Diseases
NZ785988A (en) Gut-selective sequestering agents for the treatment and prevention of autism and
NZ758692B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
HK40075263A (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
WO2023154966A1 (en) Compositions and methods for sequestering metabolites in the gastrointestinal tract
Wang et al. Alternate-day fasting ameliorates α-synuclein pathology and suppresses inflammation via the gut-brain axis in an MPTP-induced subacute mouse model of Parkinson’s disease
CN112912090A (zh) 包含细菌菌株的组合物
He et al. W2006 Beneficial Effects of Fermented Milk Containing Lactobacillus GG and L. Gasseri Tmc0356 On Regulating Intestinal Microflora and Immune Responses for Patients with Allergic Disease
NZ785569A (en) Compositions comprising bacterial strains
NZ760605B2 (en) Compositions comprising bacterial strains

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: AXIAL THERAPEUTICS, INC.

Free format text: FORMER NAME(S): AXIAL BIOTHERAPEUTICS, INC.

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired